Urogenit Tract Infect.  2017 Apr;12(1):28-34. 10.14777/uti.2017.12.1.28.

Recent Antimicrobial Susceptibilities for Uropathogenic Escherichia coli in Patients with Community Acquired Urinary Tract Infections: A Multicenter Study

• Kim WB
• Cho KH
• Lee SW
• Yang HJ
• Yun JH
• Lee KW
• Kim JM
• Kim YH
• Jeon YS
• Kim ME

• KMID: 2378146
• DOI: http://doi.org/10.14777/uti.2017.12.1.28

Abstract

PURPOSE
The aim of this study was to determine the prevalence and disease-specific antimicrobial susceptibility of Escherichia coli in urinary tract infections (UTIs).
MATERIALS AND METHODS
A total of 862 patients older than 18 years of age, who were diagnosed with UTI between January 2013 and December 2015, were included. The results of urine culture, prevalence of extended-spectrum beta lactamase (ESBL)-producing E. coli, and antimicrobial susceptibility by disease were also examined.
RESULTS
A total of 862 uropathogens were isolated. Among then, E. coli accounted for 756 (87.7%) isolates. The susceptibility rates of E. coli to the following antimicrobial agents were as follows: ampicillin 29.4%, cefazolin 70.5%, ceftazidime 75.1%, cefotaxime 75.0%, cefepime 76.2%, cefoxitin 88.8%, amoxicillin-clavulanic acid 63.6%, trimethoprim-sulfamethoxazole 60.6%, gentamicin 71.4%, ciprofloxacin 73.0%, piperacillin/tazobactam 93.9%, amikacin 99.2%, imipenem 99.1%, and ertapenem 99.3%. The frequency of ESBL-producing E. coli strains was 24.6%. The antimicrobial susceptibility of UTI varied by each disease, but without statistical significance.
CONCLUSIONS
It is necessary to regularly examine the disease-specific resistance rates to determine the appropriate empiric antibiotic treatment, and the national antibiotic usage policies must be reorganized according to the data obtained from these studies.

Keyword

Escherichia coli; Anti-bacterial agents; Susceptibility; Urinary tract infections

MeSH Terms

Amikacin
Amoxicillin-Potassium Clavulanate Combination
Ampicillin
Anti-Bacterial Agents
Anti-Infective Agents
beta-Lactamases
Cefazolin
Cefotaxime
Cefoxitin
Ceftazidime
Ciprofloxacin
Escherichia coli
Gentamicins
Humans
Imipenem
Prevalence
Trimethoprim, Sulfamethoxazole Drug Combination
Urinary Tract Infections*
Urinary Tract*
Uropathogenic Escherichia coli*
Amikacin
Amoxicillin-Potassium Clavulanate Combination
Ampicillin
Anti-Bacterial Agents
Anti-Infective Agents
Cefazolin
Cefotaxime
Cefoxitin
Ceftazidime
Ciprofloxacin
Gentamicins
Imipenem
Trimethoprim, Sulfamethoxazole Drug Combination
beta-Lactamases

Reference

1.Ronald AR., Nicolle LE., Stamm E., Krieger J., Warren J., Schaeffer A, et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents. 2001. 17:343–8.

2.Hooton TM., Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am. 1997. 11:551–81.

3.Dielubanza EJ., Schaeffer AJ. Urinary tract infections in women. Med Clin North Am. 2011. 95:27–41.

4.Flores-Mireles AL., Walker JN., Caparon M., Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015. 13:269–84.

5.Shah AA., Hasan F., Ahmed S., Hameed A. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases. Res Microbiol. 2004. 155:409–21.

6.De Backer D., Christiaens T., Heytens S., De Sutter A., Stobberingh EE., Verschraegen G. Evolution of bacterial susceptibility pattern of Escherichia coli in uncomplicated urinary tract infections in a country with high antibiotic consumption: a comparison of two surveys with a 10 year interval. J Antimicrob Chemother. 2008. 62:364–8.

7.Schito GC., Naber KG., Botto H., Palou J., Mazzei T., Gualco L, et al. The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents. 2009. 34:407–13.

8.Pitout JD. Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment. Expert Rev Anti Infect Ther. 2012. 10:1165–76.

9.Stamm WE., Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001. 183(Suppl 1):S1–4.

10.Muratani T., Matsumoto T. Bacterial resistance to antimicrobials in urinary isolates. Int J Antimicrob Agents. 2004. 24(Suppl 1):S28–31.

11.Ko YH., Oh JS., Cho DY., Bea JH., Koh SK. Changes of causative organisms and antimicrobial sensitivity of urinary tract infection between 1979 and 2001. Korean J Urol. 2003. 44:342–50.

12.Kim ME., Ha US., Cho YH. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int J Antimicrob Agents. 2008. 31(Suppl 1):S15–8.

13.Gupta K., Hooton TM., Naber KG., Wullt B., Colgan R., Miller LG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011. 52:e103–20.

14.Goettsch W., van Pelt W., Nagelkerke N., Hendrix MG., Buiting AG., Petit PL, et al. Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the Netherlands. J Antimicrob Chemother. 2000. 46:223–8.

15.Paterson DL., Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005. 18:657–86.

16.Johnson DE., Lockatell CV., Russell RG., Hebel JR., Island MD., Stapleton A, et al. Comparison of Escherichia coli strains recovered from human cystitis and pyelonephritis infections in transurethrally challenged mice. Infect Immun. 1998. 66:3059–65.

17.Johnson JR., Kuskowski MA., Gajewski A., Soto S., Horcajada JP., Jimenez de Anta MT, et al. Extended virulence genotypes and phylogenetic background of Escherichia coli isolates from patients with cystitis, pyelonephritis, or prostatitis. J Infect Dis. 2005. 191:46–50.

18.Johnson JR., Owens K., Gajewski A., Kuskowski MA. Bacterial characteristics in relation to clinical source of Escherichia coli isolates from women with acute cystitis or pyelonephritis and uninfected women. J Clin Microbiol. 2005. 43:6064–72.